A novel next‐generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys

BACKGROUND: Mim8 is a novel, next‐generation factor VIIIa mimetic in development for subcutaneous prophylactic treatment of patients with hemophilia A with and without inhibitors. In vitro and in vivo models indicate that Mim8 has a distinct hemostatic potential. OBJECTIVES: To test the nonclinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauritzen, Brian, Bjelke, Mads, Björkdahl, Olle, Bloem, Esther, Keane, Kevin, Kjalke, Marianne, Rossen, Marie, Lippert, Solvej Lund, Weldingh, Karin Nana, Skydsgaard, Mikala, Kjellev, Stine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
HAEMOSTASIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314625/
https://www.ncbi.nlm.nih.gov/pubmed/35191180
http://dx.doi.org/10.1111/jth.15682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314625/
https://www.ncbi.nlm.nih.gov/pubmed/35191180
http://dx.doi.org/10.1111/jth.15682

Ejemplares similares